Enzon drug Gets FDA Approval (NASDAQ:ENZN)

On a Monday afternoon, Enzon Pharmaceuticals made an announcement that FDA Oncologic Drug Advisory Committee has voted in the favor of and has approved the use of Pegintron as a treatment in addition to surgery in patients with metastatic melanoma. The news of FDA approval has boosted Enzon Pharmaceuticals and even the shares of the company have moved upwards on the market charts. The drug Pegintron is currently being manufactured, marketed and developed by Schering-Plough. The product is currently being used for the treatment of chronic hepatitis C in patients over 18 years of age.

Enzon Pharmaceuticals is a biopharmaceutical company that is dedicated to the development and commercialization of important life saving for patients who are suffering from cancer and other life threatening diseases. The FDA has approved that Pegintron can be used to treat patients who are older and suffering from liver diseases and those who are previously untreated with interferon alpha. Enzon’s drug Pegintron will be used with combination of Rebetol for the treatment of patients suffering from hepatitis C. During the announcement, the CEO and President of Enzon Pharmaceutical, Jeffrey H. Buchalter congratulated Schering-Plough for their achievement and for providing a better treatment option for those suffering from hepatitis C.